PCDH9-AS1

Across TCGA pan-cancer cohorts, PCDH9-AS1 RNA is linked to patient survival in 11 of 34 cancer types, making it the most broadly survival-associated PCDH9-AS1 data layer.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher PCDH9-AS1 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated PCDH9-AS1 expression acts as an unfavorable survival marker, although some lineages such as LUAD and STAD show a favorable association.

ACC, BRCA, and ESCA are the cancer types where PCDH9-AS1 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	OS	Tertile	All	0.211	0.833	<.001	81	view →
BRCA	OS	Tertile	III,IV	0.124	0.833	<.001	72	view →
ESCA	OS	Tertile	III,IV	0.074	0.563	<.001	54	view →
LIHC	OS	Tertile	All	0.195	0.783	.006	54	view →
READ	DFS	Tertile	All	0.082	0.799	<.001	45	view →
THYM	OS	Tertile	III,IV	0.212	0.953	.009	33	view →
SKCM	DFS	Tertile	III,IV	0.043	0.597	<.001	27	view →
COAD	OS	Tertile	II,III,IV	0.223	0.605	.008	24	view →
BLCA	OS	Tertile	IV	0.190	0.603	.003	18	view →
LUAD	DFS	Tertile	All	0.685	0.317	.020	18	view →
STAD	DFS	Tertile	III,IV	0.842	0.360	.033	9	view →

Pink = unfavorable, green = favorable. Showing the 11 strongest of 11 lineages.

PCDH9-AS1–ACC (OS)

Open the ACC breakdown →